Cogent Biosciences price to sales ratio COGT

Market value divided by revenue over the last twelve months, since 2019.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 38.6×; Aug 2021
8-year median: 4.6×
8-year range: 0.4× to 45.2×
Peer median: 7.8×

Cogent Biosciences' price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.

It was last meaningful in Aug 2021, at 38.6×.

On the days it had one over the last 8 years, its median was 4.6×, from 0.4× in Apr 2020 to 45.2× in Jun 2021.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2021	38.6×	3.8×	45.2×
2020	5.5×	0.4×	6.4×
2019	2.1×	1.5×	13.6×

Against its peers

Companies in Drug Manufacturers - General nearest Cogent Biosciences' size, closest first, today.

Company	Price to sales ratio
COGTCogent Biosciences	n/m
KNSAKiniksa Pharmaceuticals International	7.1×
LGNDLigand Pharmaceuticals	20.8×
AMRXAmneal Pharmaceuticals	2.1×
INDVIndivior Pharmaceuticals	3.1×
ALKSAlkermes plc.	4.4×
ARQTArcutis Biotherapeutics	8.5×
LQDALiquidia	8.5×
OGNOrganon	0.6×
TGTXTG Therapeutics	10.4×
PTGXProtagonist Therapeutics	31.8×
Peer median	7.8×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Cogent Biosciences

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.